Clinical Efficacy of Antianlotinib Combined with Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small-Cell Lung Cancer and Its Effect on Serum VEGF, CEA, and SCC-Ag

Table 2

Comparison of clinical efficacy between the study and control groups of patients.

Group	CR ( (%))	PR ( (%))	SD ( (%))	PD ( (%))	ORR ( (%))	DCR ( (%))
Study group	3 (9.38)	17 (53.13)	6 (18.75)	6 (18.75)	20 (62.50)	26 (81.25)
Control group	1 (2.78)	12 (33.33)	7 (19.44)	16 (44.45)	13 (36.11)	20 (55.56)
First-line medication
Study group	2 (6.25)	10 (31.25)	1 (3.13)	0 (0.00)	12 (37.50)	13 (40.63)
Control group	1 (2.78)	8 (22.22)	4 (11.11)	10 (27.78)	9 (25.00)	13 (36.11)
Second-line medication
Study group	1 (3.13)	7 (18.75)	5 (15.63)	6 (18.75)	8 (25.00)	13 (40.63)
Control group	0 (0.00)	4 (11.11)	3 (8.33)	6 (16.67)	4 (11.11)	7 (19.44)

, compared with the control group.